Member Info for Krone

There's no way that world leading partners in the form of ICR Johann De Bono et al are just going to let this drop. More likely they are already in the thick of discussions with potential partners.
Dr Tim Mitchell, CEO of Sareum Holdings plc, added: "....We are confident that these qualities of SRA737, based on the excellent work done to date, will be recognised and that Sierra will be successful in securing the strategic options it is seeking."

Sierra Oncology Launches Campaign Exploring Non-Dilutive Strategic Options to Support Development of its DDR Assets

- Corporate prioritization of portfolio to focus resources on advancement of momelotinib -
- Exploring non-dilutive options to support future continued development of SRA737 and SRA141 -
VANCOUVER, June 27, 2019 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today announced plans to prioritize its existing resources on the development of momelotinib, its differentiated Phase 3 drug candidate for the treatment of patients with myelofibrosis. Sierra also announced it has launched a campaign exploring non-dilutive strategic options to support the future continued development of its portfolio of potent and selective DDR (DNA Damage Response) assets, consisting of SRA737 (Chk1 inhibitor) and SRA141 (Cdc7 inhibitor).
"We recently reported compelling proof-of-concept clinical efficacy data for SRA737 at the 2019 ASCO Annual Meeting, demonstrating that this drug candidate has notable anti-cancer activity in multiple indications and a defined clinical path forward towards potential initial registration for the treatment of anogenital cancer, an indication with considerable unmet need. For SRA141, we have demonstrated a potentially novel mechanism of cytotoxicity and successfully completed the IND process with the FDA enabling the commencement of clinical trials," said Dr. Nick Glover, President and CEO of Sierra Oncology. "While we continue to advance the assets in our DDR portfolio and view them as promising oncology drug candidates that warrant further development, we are prioritizing our resources on our lead drug, momelotinib. To support the continued development of SRA737 and SRA141 in the future, we intend to seek non-dilutive strategic options."
About Sierra's DDR assets: SRA737 (targeting Chk1) and SRA141 (targeting Cdc7)
SRA737 is a potent, highly selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key regulator of cell cycle progression and the DNA Damage Response (DDR). Tumors with high levels of replication stress become reliant on Chk1 to mitigate the potentially catastrophic consequences of excess genomic instability. Intrinsic sources of replication stress can include genetic alterations in tumor suppressors, oncogenes or DNA Damage Repair genes. SRA737+LDG is a novel drug combination, where non-cytotoxic low dose gemcitabine (LDG) acts as a potent extrinsic inducer of replication stress.
At the 2019 ASCO Annual meeting, Sierra reported preliminary efficacy data for SRA737 including a 30% Overall Response Rate in patients with anogenital cancer treated with SRA737+LDG , an indication for which the second line metastatic setting represents a significant unmet medical need with no approved therapies and very poor life expecta

"We look forward to putting our strengthened financial position to work and to updating shareholders on progress as milestones are reached."....we're waiting!!!

What is the formal procedure to get Parker out?

https://wcsecure.weblink.com.au/pdf/MXC/02085750.pdf Distinct feeling of no confidence in this chap who whilst riding a number of different horses can’t by definition be giving his undivided attention to Sareum!!! Still no evidence that he had added any value whatsoever!!!

The June update stated 'The Company also has an Aurora+FLT3 inhibitor targeting haematological cancers, which is at the preclinical development stage'.
Enpoints tweet this morning indiates that there may be a space which Sareum could now fill. Notwithstanding the reported formulation issues do we know if our molecule is now dead in the water or is it still being actively progressed?
endpts.com/green-lighted-in-japan-fda-quickly-spurns-daiichi-sankyos-flawed-application-for-aml-drug/

Merck’s investors’ day tomorrow may provide some insights...

Thoth2, would you not expect ICR to be pressing Sierra to maintain momentum?

RMM thanks Tim actually refers to SIGNIFICANT value for shareholders “We believe there is a clear opportunity to generate significant value for our shareholders over the next 12 months, given recent progress with both our clinical and preclinical programmes.

Nimbus and BMS referenced but not Sareum!!! Parker et al need to be on this immediately...but will he, will he f***

Don Nicholson (@DonWNicholson) 15/06/2019, 15:16 Excellent review from last Nov. Tyk2 is the dark horse in Th17 autoimmune disorders, in my opinion. Keep an eye on cpmds from both ⁦‪@bms‬⁩ and ⁦‪@NimbusT

What’s your take on today’s update? Not sure why your post from yesterday was taken down?

Why wait until September?

Paulus47, can we afford to wait until December for the very limited opportunity that the AGM affords to address matters other than formal business.

Hi Aber, Absolutely agree, Tim and John clearly know what they are doing in the laboratory and have created some reportedly world class molecules. Selling themselves is another matter. Compare Tim to Nick Glover who could sell sand to an Arab. As for Parker, there is absolutely no evidence that he has added any value to Sareum whatsoever. He was engaged with a fanfare as the deal maker and they he would be bringing in institutional investors galore. He has done neither!! At the AGM he was in my opinion hugely defensive when challenged. This may all be part of a complicated strategy or it may be ineptitude....in the absence of any meaningful PR one worries that it’s the latter.

Fadec92 - thanks, all good stuff, the weight of empirical evidence in support of SRA737 is becoming undeniable....

“We welcome Stephen to the board, who brings with him a wealth of financial and industry experience which will be crucial to the business as we look towards the next stages of our transformation into a clinical-stage development company.”

If we are relying on Parker I would venture to suggest that we're f****d

Sierra webcast at 1300 today (http://wsw.com/webcast/jeff118/srra/)
Focus will no doubt be on Momelotinib but there may be some reference to SRA737?

Parker's latest tweet refers to SRA837......on the 1st June he referred to SEA737.....not bloody good enough from the organisational figurehead!!
There is absolutely no evidence that he has added any value whatsoever to Sareum. He was very defensive at the AGM when challenged about the lack of institutional investors and simply said 'we're working on it'...6 months later and still no progress!!
Given the huge significance of the information coming out of the ASCO conference, a few misspelt tweets simply doesn't cut the mustard. Tim and Jon are evidently busting their balls to get this off the ground and deserve much much more from their Chairman. Time for an EGM and vote of no confidence!!

Suggests milestones have been achieved?